Baseline characteristics
| Placebo | Aspirin | Ticagrelor | DAPT | Total | |
| Subjects | 31 | 31 | 29 | 29 | 120 |
| Age at randomisation | 66.3±9.2 | 68.5±7.2 | 66.5±7.7 | 69.0±10.6 | 67.5±8.7 |
| Male | 15 (48) | 12 (39) | 15 (52) | 15 (52) | 57 (47.5) |
| QRISK2 score % | 20 (12–28) | 19 (17–27) | 22 (14–27) | 24 (20–35) | 22.0 (15.5–28.0) |
| Smoking status | |||||
| Nonsmoker | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Ex-smoker | 21 (68) | 20 (65) | 21 (72) | 21 (72) | 83 (69.2) |
| Light smoker (<10 pack-years) | 3 (10) | 0 (0) | 1 (3) | 3 (10) | 7 (5.8) |
| Moderate smoker (10–19 pack-years) | 5 (16) | 9 (29) | 5 (17) | 4 (14) | 23 (19.2) |
| Heavy smoker (≥20 pack-years) | 2 (6) | 2 (6) | 2 (7) | 1 (3) | 7 (5.8) |
| Diabetes status | |||||
| Type 1 | 0 (0) | (0) | 2 (7) | 3 (10) | 5 (4.2) |
| Type 2 | 2 (6) | 3 (10) | 2 (7) | 3 (10) | 10 (8.3) |
| Angina or heart attack in a first-degree relative aged <60 years? Yes | 10 (32) | 6 (19) | 7 (24) | 9 (31) | 32 (26.7) |
| On blood pressure treatment? Yes | 10 (32) | 9 (29) | 12 (41) | 13 (45) | 44 (36.7) |
| Rheumatoid arthritis? Yes | 0 (0) | 1 (3) | 3 (10) | 1 (3) | 5 (4.2) |
| Cholesterol/HDL ratio | 3.0 (2.2–4.0) | 2.8 (2.4–4.1) | 3.0 (2.6–3.6) | 3.1 (2.4–3.6) | 2.9 (2.4–3.8) |
| Systolic blood pressure mmHg | 145.7 (16.1) | 144.6 (18.2) | 143.1 (14.7) | 144.5 (22.1) | 144.5 (17.7) |
| Height cm | 167.5 (9.9) | 163.0 (10.5) | 164.6 (11.3) | 166.9 (10.9) | 165.5 (10.7) |
| Weight cm | 74.7 (18.2) | 73.1 (17.4) | 72.2 (18.7) | 79.9 (18.5) | 74.9 (18.2) |
| BMI kg·m−2 | 26.5 (5.4) | 27.4 (5.6) | 26.5 (5.7) | 28.9 (7.0) | 27.3 (6.0) |
| COPD disease category# | |||||
| Severe (FEV1 <30% pred) | 8 (27) | 6 (19) | 6 (21) | 5 (17) | 25 (21.0) |
| Moderate (FEV1 30–49% pred) | 10 (33) | 14 (45) | 7 (24) | 11 (38) | 42 (35.3) |
| Mild (FEV1 50–79% pred) | 12 (40) | 11 (35) | 16 (55) | 13 (45) | 52 (43.7) |
| Daily sputum producer >3 months in each of last 2 year? Yes | 22 (71) | 15 (48) | 18 (62) | 15 (52) | 70 (58.3) |
| Number of acute exacerbations of COPD treated in past 12 months | 4.2 (4.5) | 3.4 (3.1) | 2.6 (3.1) | 2.5 (2.0) | 3.2 (3.3) |
| Number of hospitalisation in past 12 months for COPD | 0.6 (1.2) | 0.4 (1.6) | 0.4 (0.9) | 0.2 (1.0) | 0.4 (1.2) |
Data are presented as n, mean±sd, n (%) or median (interquartile range). DAPT: dual antiplatelet therapy; HDL: high-density cholesterol; BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s. #: National Institute for Health and Care Excellence Clinical guideline (June 2010).